Statins are widely used in the treatment of patients having high levels of serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). However, there is little documentation on the ability of statins to treat dyslipidemia induced by second-generation antipsychotics (sGAs) and if so, to what extent. A goal of the present study was to evaluate these aspects among psychotic inpatients who were prescribed sGAs in a typical clinical setting. The study sample consisted of 28 psychotic male forensic psychiatric inpatients (mean age 44 years). All had sGA medication for their psychotic symptoms. secondary causes of dyslipidemia were excluded and statin therapy was initiated, according to the established guidelines. The change in TC, LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) levels were evaluated retrospectively and analysed by the Wilcoxon signed Ranks test. The lowering effectivity of statin treatment was 36% for TC, 49% for LDL-C and 29% for TG. Most of the patients (84%) achieved a target value for LDL-C of <3.0 mmol/L, and 54% achieved target value of <2.6 mmol/L, while HDL-C remained unchanged. These results were achieved with a low or moderate dose of statin during a period of 1 month. The effect of statins in lowering of TC, LDL-C and TG among dyslipidemic psychiatric patients that were treated with sGA was similar to the effectiveness of statin therapy in other clinical trial settings, and should be used when they are indicated.
Atmaca M., Kuloglu M., Tezcan E., Ustundag B. (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry64: 598—604
2.
Brown S. (1997) Excess mortality of schizophrenia. A meta-analysis . Br J Psychiatry171: 502—506
3.
Brown S., Hazel I., Barraclough B. (2000) Causes of excess mortality of schizophrenia. Br J Psychiatry177: 212—217
Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., Lindenmayer J.P., Manoukian S.V., Banerji M.A., Lebovitz H.E., Hennekens C.H. (2004) Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia . J Clin Psychiatry65(Suppl 7): 4—18
6.
Correll U.C., Frederickson A.M., Kane J.M., Manu P. ( 2006) Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry67: 575—583
7.
De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., Ebrahim S., Faergeman O., Graham I., Mancia G., Cats V.M., Orth-Gomer K., Perk J., Pyorala K., Rodicio J.L., Sans S., Sansoy V., Sechtem U., Silber S., Thomsen T., Wood D.; Third Joint Force of European and other Societies on Cardiovascular Disease and Prevention in Clinical Practice (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force for European and Other Societies on cardiovascular disease prevention in clinical practice. Eur Heart J24: 1601—1610
8.
Deedwania P.C., Hunninghake D.B., Bays H.E., Jones P.H., Cain V.A., Blasetto J.W.; STELLAR Study Group (2005) Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol95: 360—366
9.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) ( 2002) High Blood Cholesterol. Third Report of the National Cholesterol Education Program (NCEP) Final Report. National Cholesterol Education Program . National Health, Lung and Blood Institute, National Institute of Health. NIH Publication No. 02-5215.
10.
Finnish Society of Internal Medicine (2004 ) Dyslipidemias. Practical guidelines (Suomen Sisätautilääkärien yhdistys ry:n asettama työryhmä. Dyslipidemiat. Käypä hoito -suositus. In Finnish). Duodecim120: 1794—1816
11.
Friday K.E. (2003) Aggressive lipid management for cardiovascular prevention: evidence from clinical trials. Exp Biol Med (Maywood) 228: 769—778
12.
Friedewald W.T., Levi R.I., Fredrickson D.S. (1972) Estimation of the concentration of low density lipoproteins cholesterol in plasma without use of ultracentrifuge. Clin Chem18: 499—502
13.
Furst B.A., Champion K.M., Pierre J.M., Wirshing D.A., Wirshing W.C. (2002) Possible association on QTc interval prolongation with coadministration of quetiapine and lovastatin. Biol Psychiatry51: 264—265
14.
Giner V., Munoz R., Redon J. (2002) Risperidone and severe cerivastatininduced rhabdomyolysis . J Intern Med251: 177—178
15.
Henderson D.C. (2001) Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry62(Suppl 23): 39—44
16.
Henderson D.C., Nguyen D.D., Copeland P.M., Copeland P.M., Hayden D.L., Borba C.P., Louie P.M., Freudenreich O., Evins A.E., Cather C., Goff D.C. (2005) Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study . J Clin Psychiatry66: 1116—1121
17.
Jones P.H., Davidson M H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., Blasetto J.W., STELLAR Study Group (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (Stellar trial). Am J Cardiol92: 152—160
18.
Lamberti J.S., Olson D., Crilly J.F., Olivares T., Williams G.C., Tu X., Tang W., Wiener K., Dvorin S., Dietz M.B. (2006) Prevalence of metabolic syndrome among patients receiving clozapine. Am J Psychiatry163: 1273—1276
19.
Law M.R., Wald N.J., Rudnicka A.R. (2004) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis . Br Med J326: 1423—1427
20.
Law M.R., Rudnica A.R. (2006) Statin safety: a systematic review. Am J Cardiol97: 52—60
21.
Lindenmayer J., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. (2003) Changes in glucose and cholesterol levels in patients with typical or atypical antipsychotics. Am J Psychiatry160: 290—296
22.
Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., Kane J.M., Lieberman J.A., Schooler N.R., Covell N., Stroup S., Weissman E.M., Wirshing D.A., Hall C.S., Pogach L., Pi-Sunyer X., Bigger J.T. Jr, Friedman A., Kleinberg D., Yevich S.J., Davis B., Shon S. ( 2004) Physical health monitoring of patients with schizophrenia . Am J Psychiatry161: 1334—1349
23.
Newcomer J.W. (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNCDrugs19(Suppl 1): 1—93
24.
Newman S.C., Bland R.C. (1991) Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry36: 239—245
25.
Räsänen S., Hakko H., Viilo K., Me yer-Rochow V.B., Moring J. (2003) Excess mortality among long-stay psychiatric patients in Northern Finland. Soc Psychiatry Psychiatr Epidemiol38: 297—304
26.
Talbert R.L. (2006) Safety issues with statin therapy. J Am Pharm Assocc46: 479—488
27.
Webber M.A., Mahmud W., Lightfoot J.D., Shekhar A. (2004) Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol18: 432—434
28.
Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., Wirshing W.C. (2002) The effect of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry63: 856—865
29.
Worz C.R., Bottorff M. (2003) Treating dyslipidemic patients with lipid-modifying and combination therapies. Available at http://www.medscape.co/viewarticle/455750
30.
Young I.S. (2005) Lipids for psychiatrists—an overview. J Psychopharmacol19(Suppl 6): 66—75
